Eric K. Singhi, MD

Learn why paired tissue and liquid NGS at diagnosis and progression uncovers actionable NSCLC alterations, guiding trials and future monitoring.

Explore NSCLC precision oncology gaps: expand targets beyond EGFR, refine liquid biopsies and MRD, and fix incomplete NGS testing.

Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.

How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.

Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.

Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.

See how KRAS mutations, especially G12C, guide NSCLC treatment sequencing—from PD-L1 strategy to sotorasib/adagrasib and emerging trials.

Experts unpack NGS, ctDNA and protein testing to speed actionable biomarker detection and guide targeted therapy choices in advanced lung cancer.

Experts explain combining tissue NGS, ctDNA liquid biopsy and IHC to uncover actionable NSCLC biomarkers and guide first-line targeted therapy.

Discover why combining tissue NGS, ctDNA and IHC uncovers actionable NSCLC biomarkers, shaping first-line therapy, resistance, and new ADC options.

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

Eric K. Singhi, MD, discuses the emerging role of TROP2-directed antibody–drug conjugates in the evolving treatment algorithm for NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss treatment and sequencing considerations in advanced non–small cell lung cancer.

Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.

Dr. Eric Singhi presents preliminary findings from the Phase I/II SOHO-01 trial, demonstrating that the oral HER2-targeted tyrosine kinase inhibitor BAY 2927088 achieves high response rates and durable disease control in patients with pretreated HER2-mutant NSCLC, with a manageable safety profile.

Eric Kumar Singhi, MD, discusses the identification of current care gaps and unmet needs in small cell lung cancer.

Eric Kumar Singhi, MD, discusses unmet needs in the management of small cell lung cancer, highlighting how the ADRIATIC study addressed these needs.

Eric Kumar Singhi, MD, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer.

Eric K. Singhe, MD, of The University of Texas MD Anderson Cancer Center, discusses the journey of non–smell cell lung cancer treatment through mentorship, advocacy, and more.